Novavax, Inc. (NVAX)

Fundamentals are weak and highly variable: the recent run-rate has reverted to losses and cash burn after non-recurring 2025 items rolled off, even though liquidity remains adequate and partnerships provide optionality. Earnings-based valuation is not meaningful with negative trailing profits; EV/Sales is moderate but free cash flow yield is negative and discounted-cash-flow outputs are negative. Risk remains elevated due to dependence on partners, regulatory outcomes, and high volatility.

Recent coverage is dominated by the Aug 6 Q2 2026 results release (announced) with a neutral tone and limited follow-through; the media sentiment delta is indeterminate because the 30–90d baseline pull was unavailable (primary tier returned zero and the aggregator retry timed out). Legal/investigation screens surfaced no regulator-confirmed actions and Reddit signal quality was effectively empty, leaving a post-earnings digestion setup without a clear near-term driver.

The near-term trend has improved, with price above SMA20 and the 9/21-day EMA stack plus a positive MACD histogram, and liquidity easily clears the floor. However, price remains below the 50-day and 200-day SMAs, MACD is still below zero, and RSI is neutral, leaving a mixed repair chart rather than a high-conviction bullish trend.